Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Apr 30;24(1):187.
doi: 10.1186/s13054-020-02897-4.

Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia

Nikoletta Rovina  1 , Karolina Akinosoglou  2 , Jesper Eugen-Olsen  3 , Salim Hayek  4 , Jochen Reiser  5 , Evangelos J Giamarellos-Bourboulis  6   7
Affiliations

Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia

Nikoletta Rovina et al. Crit Care. .
No abstract available

Keywords: COVID-19; Prognosis; Respiratory failure; suPAR.

PubMed Disclaimer

Conflict of interest statement

JEO is a co-founder, shareholder, and CSO of ViroGates A/S, Denmark. JEO is an inventor on patents on suPAR owned by Copenhagen University Hospital Hvidovre, Denmark.

JR is a co-founder and shareholder of Trisaq, a biopharmaceutical company that develops drugs that target suPAR.

EJGB has received honoraria from AbbVie USA, Abbott CH, InflaRx GmbH, MSD Greece, XBiotech Inc., and Angelini Italy; independent educational grants from AbbVie, Abbott, Astellas Pharma Europe, AxisShield, bioMérieux Inc., InflaRx GmbH, and XBiotech Inc.; and funding from the FrameWork 7 program HemoSpec (granted to the National and Kapodistrian University of Athens), the Horizon2020 Marie-Curie Project European Sepsis Academy (granted to the National and Kapodistrian University of Athens), and the Horizon 2020 European Grant ImmunoSep (granted to the Hellenic Institute for the Study of Sepsis).

All other authors have disclosed that they do not have any conflicts of interest relevant to this submission.

Figures

Fig. 1
Fig. 1
suPAR as an early predictor of the development of severe respiratory failure (SRF). a Admission levels of suPAR among Greek patients who eventually developed or not SRF. The p value of comparisons by the Mann-Whitney U test is provided. b Levels of suPAR in patients with COVID-19 and controls. The p value of comparisons by the Mann-Whitney U test is provided. c Time to SRF of Greek patients in relation to the admission levels of suPAR. CI, confidence interval; HR, hazard ratio
See this image and copyright information in PMC

Comment in

References

    1. Guan W, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020. 10.1056/NEJMoa2002032. - PMC - PubMed
    1. Pixley RA, Espinola RG, Ghebrehiwet B, Joseph K, Kao A, Bdeir K, et al. Interaction of high-molecular-weight kininogen with endothelial cell binding proteins suPAR, gC1qR and cytokeratin 1 determined by surface plasmon resonance (BiaCore) Thromb Haemost. 2011;105:1053–1059. doi: 10.1160/TH10-09-0591. - DOI - PMC - PubMed
    1. Schultz M, Rasmussen LJH, Høi-Hansen T, Kjøller E, Jensen BN, Lind MN, et al. Early discharge from the emergency department based on soluble urokinase plasminogen activator receptor (suPAR) levels: a TRIAGE III substudy. Dis Markers. 2019;2019:3403549. doi: 10.1155/2019/3403549. - DOI - PMC - PubMed
    1. Hayek SS, Leaf DE, Samman Tahhan A, Raad M, Sharma S, et al. Soluble urokinase receptor and acute kidney injury. N Engl J Med. 2020;382:416–426. doi: 10.1056/NEJMoa1911481. - DOI - PMC - PubMed
    1. Giamarellos-Bourboulis EJ, Norrby-Teglund A, Mylona V, Savva A, Tsangaris I, Dimopoulou I, et al. Risk assessment in sepsis: a new prognostication score by APACHE II score and serum soluble urokinase plasminogen activator receptor. Crit Care. 2012;16:R149. doi: 10.1186/cc11463. - DOI - PMC - PubMed

Publication types

Substances